Inferring effects of mutations on SARS-CoV-2 transmission from genomic surveillance data.

Publication date: Jan 07, 2025

New and more transmissible variants of SARS-CoV-2 have arisen multiple times over the course of the pandemic. Rapidly identifying mutations that affect transmission could improve our understanding of viral biology and highlight new variants that warrant further study. Here we develop a generic, analytical epidemiological model to infer the transmission effects of mutations from genomic surveillance data. Applying our model to SARS-CoV-2 data across many regions, we find multiple mutations that substantially affect the transmission rate, both within and outside the Spike protein. The mutations that we infer to have the largest effects on transmission are strongly supported by experimental evidence from prior studies. Importantly, our model detects lineages with increased transmission even at low frequencies. As an example, we infer significant transmission advantages for the Alpha, Delta, and Omicron variants shortly after their appearances in regional data, when they comprised only around 1-2% of sample sequences. Our model thus facilitates the rapid identification of variants and mutations that affect transmission from genomic surveillance data.

Open Access PDF

Concepts Keywords
Genomic COVID-19
Pandemic Genome, Viral
Protein Genomics
Surveillance Humans
Viral Mutation
Pandemics
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2

Semantics

Type Source Name
disease IDO protein
disease MESH viral load
disease IDO host
drug DRUGBANK Water
disease MESH Infection
disease MESH Infectious Diseases
disease IDO process
disease MESH secondary infections
pathway REACTOME Reproduction
disease IDO history
pathway KEGG Viral replication
disease IDO infectivity
disease IDO replication
drug DRUGBANK Coenzyme M
disease MESH long term infections
disease MESH influenza
drug DRUGBANK Aspartame
drug DRUGBANK P-nitrobiphenyl
disease IDO site
disease IDO pathogen
disease IDO infected population
disease MESH infection transmission
drug DRUGBANK Potassium
disease IDO quality
drug DRUGBANK Isoxaflutole
disease MESH uncertainty
drug DRUGBANK Ademetionine
disease MESH hepatitis
disease MESH COVID 19
disease IDO cell
disease MESH severe acute respiratory syndrome
disease MESH SD1
drug DRUGBANK Ranitidine
pathway REACTOME Infectious disease
disease IDO infectious disease
drug DRUGBANK L-Aspartic Acid
drug DRUGBANK Vorinostat
drug DRUGBANK Efavirenz

Original Article

(Visited 1 times, 1 visits today)